– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease –

– In participants with chronic kidney disease and baseline albuminuria, lorundrostat significantly reduced urine albumin-to-creatinine ratio –

– Lorundrostat demonstrated a favorable safety profile in participants with and without chronic kidney disease over 12 weeks –

RADNOR, Pa., May 30, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today presented new clinical data for lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) in Gdańsk, Poland.

“Despite the availability of current therapies, up to 75 percent of patients with chronic kidney disease still have uncontrolled or resistant blood pressure, contributing to a high risk of cardiovascular events and kidney disease progression,” said Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. “These results, together with our Explore-CKD trial findings, demonstrate lorundrostat’s potential to address the compounded burden of hypertension and CKD, underscoring its promise as an important potential treatment option for this difficult-to-treat population with high unmet need.”

The analysis evaluated the efficacy and safety of once-daily lorundrostat 50 mg by CKD status among 800 participants with uncontrolled or resistant hypertension enrolled in the randomized, double-blind, placebo-controlled Phase 3 Launch-HTN trial. Among participants with CKD (n=192), 71% were receiving three or more anti-hypertensive medications at baseline, compared with 56% of those without CKD. In addition, 31% of participants with CKD had systolic blood pressure (SBP) ≥160 mmHg at baseline, versus 17% of participants without CKD.

Lorundrostat demonstrated significant reductions in SBP that were comparable between CKD and non-CKD participants. At week 12, placebo-adjusted SBP reductions were 9.6 mmHg in participants with CKD (p=0.0022) and 12.2 mmHg in those without CKD (p<0.0001). A greater proportion of lorundrostat-treated participants also achieved target SBP of <130 mmHg at week 12 compared with placebo, both among CKD participants (44% vs 18%) and non-CKD participants (48% vs 22%).

Lorundrostat treatment was also associated with a significant placebo-adjusted reduction in urinary albumin-to-creatinine ratio (UACR) among 84 participants with CKD and baseline albuminuria, achieving a 52.2% placebo-adjusted reduction at 12 weeks (p<0.0001). Lorundrostat had a favorable safety profile in both CKD and non-CKD participants with low rates of confirmed hyperkalemia, 2.4% and 0% respectively.

“These findings are compelling because they show that lorundrostat achieves comparable blood pressure reductions regardless of kidney disease status, while also significantly reducing albuminuria, a key marker of kidney injury and disease progression, in these patients,” said Dr. Liffert Vogt, Professor of Nephrology and Renal Transplantation at Amsterdam University Medical Center and University of Amsterdam. “Aldosterone is a key driver of both chronic kidney disease and difficult-to-treat hypertension, and these findings demonstrate the potential for lorundrostat to provide needed cardiorenal protection for these patients.”

Previous data from the Explore-CKD trial, presented at ASN Kidney Week 2025, showed that adding lorundrostat to standard-of-care therapy reduced both blood pressure and albuminuria in participants with hypertension and CKD. Across both the Launch-HTN and Explore-CKD trials, lorundrostat demonstrated clinically meaningful blood pressure reductions in participants with hypertension, including those in high-risk populations with CKD, obesity and Black or African American participants.

Lorundrostat is currently under review by the U.S. Food and Drug Administration, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.

About Launch-HTN 
Launch-HTN (NCT06153693) was a global, randomized Phase 3 double-blind, placebo-controlled trial of adults whose blood pressure remained uncontrolled despite being on two to five antihypertensive medications. Participants were assigned to one of three groups: placebo; lorundrostat 50 mg once daily; or lorundrostat 50 mg once daily with the option to increase to 100 mg at week six. The primary endpoint was change from baseline in SBP at 6 weeks versus placebo, measured by automated office blood pressure monitoring.

About Chronic Kidney Disease (CKD)
CKD, which is characterized by the gradual loss of kidney function, is estimated to affect more than 10% of the global population and is one of the leading causes of mortality worldwide. According to the U.S. Centers for Disease Control and Prevention (CDC), more than 1 in 10 of adults aged 18 or older (37 million people) are estimated to have CKD. Approximately 21% of adults with high blood pressure are estimated to have CKD. The relationship between these conditions is tightly linked: sustained hypertension may contribute to impaired kidney function, and progressive decrease in kidney function may lead to worsening blood pressure (BP) control. When CKD is present in patients with hypertension, the risk of cardiovascular disease and mortality rises significantly.

Emerging evidence points to dysregulated aldosterone as a key driver of both diseases. Excess aldosterone promotes sodium retention, vascular inflammation and fibrosis, contributing to both uncontrolled BP and kidney injury. Despite the availability of existing therapies, a significant proportion of patients remain uncontrolled or undertreated. Early detection and targeted interventions that address underlying mechanisms, such as aldosterone dysregulation, may offer the potential to slow CKD progression, reduce cardiovascular risk and improve long-term outcomes. Without effective management, CKD can advance to kidney failure, requiring dialysis or transplantation.

About Hypertension
Having sustained, elevated blood pressure (BP) (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the United States. In 2022, more than 685,000 deaths in the United States included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an estimated annual economic burden of about $219 billion in the United States in 2019.

Less than 50% of hypertensive patients achieve their BP goal with currently available medications. Dysregulated aldosterone levels are a key factor in driving hypertension in approximately 30% of all hypertensive patients.

About Lorundrostat
Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as CKD, OSA and other diseases driven by dysregulated aldosterone. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in hypertensive participants.

Mineralys has now completed six late-stage clinical trials of lorundrostat supporting the efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. This includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the robust, durable and clinically meaningful reductions in systolic BP by lorundrostat. Lorundrostat was generally well tolerated in both trials with a favorable safety profile.

About Mineralys
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.

Forward-Looking Statements
Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the anticipated timing of the U.S. Food and Drug Administration’s (FDA) review of our accepted New Drug Application (NDA) and any subsequent regulatory approval of lorundrostat; and the planned future clinical development of lorundrostat and the timing thereof. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: topline results that we report are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; any delays in the FDA’s review of our accepted NDA, including as a result of a government shutdown or reductions in agency funding or personnel, the results of our clinical trials, including the Advance-HTN and Launch-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat; later developments with the FDA may be inconsistent with the feedback from prior meetings, including whether the proposed pivotal program will support registration of lorundrostat following the FDA’s review of our NDA submission; our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, and the potential for a local and/or global economic recession; our ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Tanabe Pharma Corporation to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

Investor Relations
investorrelations@mineralystx.com

Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com

The post Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) appeared first on Crypto Insider.

NEW YORK, May 30, 2026 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SES AI Corporation (NYSE: SES) between January 29, 2025 and March 4, 2026, both dates inclusive (the “Class Period”), of the important June 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased SES AI securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the SES AI class action, go to https://rosenlegal.com/submit-form/?case_id=56471 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 26, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) SES AI overstated its business prospects by materially overstating the expected results that could be achieved by deals with companies that have limited or no operations; (2) SES AI created an appearance of revenue by purchasing services in exchange for purchases of Molecular Universe; (3) contrary to its positive statements regarding growth prospects, SES AI was affected by material logistics constraints in the fourth quarter of 2025 which would materially affect Q4 2025 revenues; (4) the foregoing called into question SES AI’s growth prospects for 2026, which were confirmed due to lower-than expected 2026 revenue guidance; and (5) as a result, defendants’ statements about SES AI’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the SES AI class action, go to https://rosenlegal.com/submit-form/?case_id=56471 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40^th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com

The post SES AI DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages SES AI Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SES appeared first on Crypto Insider.

ALBANY, N.Y., May 29, 2026 (GLOBE NEWSWIRE) — The New York State Builders Association (NYSBA) today applauded Governor Kathy Hochul and the New York State Legislature for enacting transformational reforms to the State Environmental Quality Review Act (SEQRA) as part of the 2026-2027 State Budget, signed into law today by the Governor.

The reforms represent one of the most significant changes to New York’s environmental review process in decades and mark a major step forward in streamlining housing production, accelerating economic development, and addressing New York’s ongoing affordability crisis.

After months of intensive negotiations and collaboration among stakeholders, the final legislation delivers long-overdue changes that will help remove unnecessary barriers to housing creation, encourage smart growth and investment, and make it easier to build the homes New Yorkers desperately need.

“Governor Hochul demonstrated the kind of pragmatic, results-driven leadership New York desperately needed by bringing together stakeholders and securing one of the most consequential SEQRA reforms in generations,” said Bruno Schickel, President of the New York State Builders Association. “The Governor not only achieved the transformational reforms she fought for, but delivered meaningful changes that will help streamline housing production, spur economic development, and address New York’s growing affordability crisis. These long-overdue reforms will create new opportunities for working families, support responsible growth, and help move critically needed housing projects forward across the State.”

NYSBA also thanked Senate Majority Leader Andrea Stewart-Cousins, Assembly Speaker Carl Heastie, and members of the State Legislature for their leadership and partnership in advancing the legislation.

“This is a tremendous victory for housing, for economic opportunity, and for the future of New York,” Schickel added. “Congratulations to Governor Hochul and everyone involved in making this historic achievement possible.”

The New York State Builders Association has long advocated for balanced and effective SEQRA reforms that protect the environment while ensuring New York can meet its pressing housing and economic development needs.

FOR MORE INFORMATION, PLEASE CONTACT:
New York State Builders Association
Email: info@nysba.com | Phone: 518-465-2492

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e027f0e7-800f-4a06-9706-6bdc454bd1fc

The post New York State Builders Association Applauds Governor Hochul and State Legislature for Historic SEQRA Reforms appeared first on Crypto Insider.

NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Globant S.A. (NYSE: GLOB) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Globant securities between February 15, 2024 and August 14, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/GLOB.

Globant Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:

1. Globant’s touted “Latin American pivot” was not successful and the Company’s Latin American operations were experiencing declining demand, client defections, and project cancellations; 
2. contrary to Defendants’ claims that Globant was a market leader and employer of choice in the region, the Company froze employee wages in Mexico and Argentina, triggering widespread employee turmoil and degrading client services; and 
3. as a result of the foregoing, Defendants’ positive statements regarding Globant’s business, operations, and prospects in Latin America were materially misleading.
   

What’s Next for Globant Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/GLOB. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Globant you have until June 23, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.

No Cost to Globant Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Globant Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.
Prior results do not guarantee similar outcomes.

The post Bronstein, Gewirtz & Grossman LLC Urges Globant S.A. Investors to Act: Class Action Filed Alleging Investor Harm appeared first on Crypto Insider.

Washington, DC, May 28, 2026 (GLOBE NEWSWIRE) — New research from Children’s National Hospital and the National Institutes of Health (NIH) is offering one of the most comprehensive insights yet into how COVID-19 affects children over time, highlighting both areas of concern and reassuring findings for families and clinicians.

The Pediatric COVID Outcomes Study (PECOS) led by Roberta DeBiasi, MD, MS, chief of the division of Pediatric Infectious Diseases at Children’s National and Gina Montealegre Sanchez, MD, MS, pediatric rheumatologist at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), provides crucial guidance for understanding pediatric COVID-19 outcomes.
The research teams behind these three papers examined overall symptom burden, behavioral health and cardiology outcomes in hundreds of children and adolescents, comparing those who had COVID-19 with those who did not.

“This study included mostly children with mild COVID-19 similar to what was seen during the pandemic period and results should be interpreted accordingly,” said study author and co-principal investigator, Dr. Montealegre Sanchez.

Long-COVID symptoms identified and tracked
As the first and largest study of its kind in the U.S. to publish longitudinal data, researchers reported on symptoms that children experienced in the first 12 months after enrollment in the study. They identified 20 symptoms more commonly reported in those who had COVID-19, including headaches, fatigue, forgetfulness, gastrointestinal issues, malaise and respiratory issues. Symptoms varied by age, with some appearing early and others persisting or emerging months later.

“This study helps us understand how post-COVID symptoms in children evolve over time, and importantly, across different age groups,” said Alexandra Yonts, MD, infectious diseases specialist at Children’s National and co-lead author of the study. “Since childhood is such a dynamic period of growth and development, tracking these symptoms at multiple time points and in children of many different ages is critical to know what the true long-term impacts of SARS-CoV-2 infection look like in the pediatric population.”

Physical health impacted, but mental health effects widespread
In another research project conducted with more than 800 youth who participated in the broader PECOS study, researchers found that children who had COVID-19 reported worse global health, reduced physical and cognitive functioning, and increased fatigue, pain and sleep disturbances. However, rates of anxiety and depression were similar between infected and uninfected children.

“The pandemic has affected all children’s mental health, not just those who were infected,” said research paper author Linda Herbert, PhD, director of Psychology Research and Clinical Services, Allergy and Immunology at Children’s National. “These findings highlight the broad impact of this experience on an entire generation.”

No evidence of heart damage in children
In reassuring news, a third prospective project found no evidence that COVID-19 causes long-term heart damage in children. Using advanced imaging, researchers observed no differences in cardiac function between infected and uninfected youth or even before and after infection. Children reporting symptoms such as chest pain or fatigue also had normal heart function.
“While some children experience these seemingly cardiac symptoms, our findings show these are not linked to underlying heart dysfunction,” said research paper author Michael He, MD, cardiology fellow at Children’s National.

A clearer path forward for care
Together, these findings help distinguish between the direct effects of COVID-19 infection and the broader impacts of the pandemic itself. The findings will help guide screening, clinical care and reassurance for families navigating post-COVID concerns.

The post New research reveals COVID-19’s long-term impact on kids appeared first on Crypto Insider.

WASHINGTON, D.C., May 28, 2026 (GLOBE NEWSWIRE) — The United States Mint (Mint) will release the Best of the Mint 1916 Mercury Dime Gold Coin and Silver Medal Set—the first of five numismatic gold coin and companion silver medal sets celebrating the Mint’s special journey through history—on June 4, 2026, at noon EDT. Orders are limited to one set per household for 24 hours, beginning from the on-sale release date and time.

In honor of the 250th anniversary of U.S. independence, the Mint curated a list of 21 historic coins spanning our Nation’s history, from its founding in 1792 to the 21^st century. Following public input and expert recommendation, five Best of the Mint coins were selected for this special series: the 1916 Mercury Dime, the 1916 Standing Liberty Quarter Dollar, the 1916 Walking Liberty Half Dollar, the 1804 Silver Dollar, and the 1907 Saint-Gaudens High Relief $20 Gold Coin.

The Best of the Mint 1916 Mercury Dime Gold Coin and Silver Medal Set features a 24-karat one-tenth ounce fine gold coin and a one-ounce medal made of 99.9% fine silver. Pricing for this product is in accordance with the United States Mint pricing range table for gold coins.

Customers may sign up for a “Remind Me” alert for this set or view other Semiquincentennial Numismatic products.

1916 Mercury Dime 24K Gold Coin

The coin’s obverse (heads) depicts Liberty in profile facing left, wearing a winged cap symbolizing freedom of thought. Inscriptions are “LIBERTY,” “IN GOD WE TRUST,” and “1916.” To commemorate the Semiquincentennial of our Nation’s founding, the coin features a unique Liberty Bell privy mark with the numeral “250.” The coin’s reverse (tails) depicts a fasces (a bundle of rods) to symbolize strength through unity. The battle ax and the olive branch represent America’s military readiness and her desire for peace. Inscriptions are “UNITED STATES OF AMERICA,” “E PLURIBUS UNUM,” and “ONE DIME.”

1916 Mercury Dime – Inspired Silver Medal

Also known as the Winged Liberty Dime, the medal’s obverse features a design that spans from obverse to reverse and reflects the original coin’s period of circulation from 1916 through 1945. The design represents years of great change and upheaval for the United States, both domestically and abroad. Observing that the United States would enter two world wars during this period, Liberty is depicted in both defensive and offensive postures.

The medal’s reverse design extends to the reverse with rays emitting from Liberty’s sword, symbolic of hope at the end of conflict. The Great Depression is represented by the Hooverville shacks, and the swirling waves in the background represent the Dust Bowl. The inscription is “1916–1945.”

About the United States Mint

Congress created the United States Mint in 1792, and the Mint became part of the Department of the Treasury in 1873. As the Nation’s sole manufacturer of legal tender coinage, the Mint is responsible for producing circulating coinage for the Nation to conduct its trade and commerce. The Mint also produces numismatic products, including proof, uncirculated, and commemorative coins; Congressional Gold Medals; silver and bronze medals; and silver and gold bullion coins. Its numismatic programs are self-sustaining and operate at no cost to taxpayers.

Additional Resources

• Sign up to receive electronic product notifications, news releases, public statements, and our monthly educational newsletter, Lessons That Make Cents.
• Follow us on Facebook, X, and Instagram; visit and subscribe to our YouTube channel.

The post United States Mint Releases Best of the Mint 1916 Mercury Dime Gold Coin and Silver Medal Set appeared first on Crypto Insider.

SALT LAKE CITY, May 27, 2026 (GLOBE NEWSWIRE) — Breeze Airways, the high-value, low-cost airline combining affordable fares and modern amenities for a Seriously Nice travel experience, today celebrates its fifth anniversary with a network-wide promotion offering 45% off flights.

Since its inaugural flight from Tampa to Charleston on May 27, 2021, Breeze has grown from 16 cities to 88 across 35 states and five countries. Its fleet of 52 brand-new Airbus A220-300 aircraft — one of the youngest and most fuel-efficient narrowbody fleet in the U.S. — not only deliver a high-quality onboard experience, but also make it possible to keep fares low while operating more than 300 routes nationwide.

“Five years ago, we set out to prove that travelers shouldn’t have to choose between a low fare and a good experience — that you really can have your cake and eat it too,” said David Neeleman, Breeze Airways founder and CEO. “In that time, we’ve become the fastest-growing airline in the country – increasing seat capacity by more than 40% last year alone while improving profitability. It’s evidence that we’re achieving our purpose of ‘Nice people, flying nice people, to nice places.’”

Redefining Affordable Air Travel

When Breeze launched in 2021, millions of travelers in dozens of mid-sized markets such as Providence, R.I., and Raleigh-Durham, N.C., were forced to fly through congested hubs or required to sacrifice comfort and quality for an affordable fare. Breeze was built to change that — offering convenient, nonstop flights on brand-new aircraft with a high-value offering that allows Guests to select only the amenities they desire in addition to benefitting from nice policies such as free family seating and no change fees and easy self-service technology delivered through the airline’s highly-rated app.

In the five years since the hybrid carrier took flight, Breeze has grown capacity 47% year over year while retaining 95% of the markets it has entered since launch. The airline now operates from 13 bases and is number one in terms of destinations served in 34 of its markets.

Earlier this month, Breeze was listed on the TIME100 Most Influential Companies list for 2026, including being named one of 10 Industry Leaders for travel and tourism. The airline has also been recognized as one of Fast Company’s “World’s Most Innovative Companies” for 2025, “Best Major Airline in North America” by the Airline Passenger Experience Association (APEX), and a top 4 “Best Domestic Airline” by Travel + Leisure for four consecutive years.

“Breeze was built to fill a real gap, and five years in; the numbers prove it,” said Neeleman. “We’re growing faster than anyone else in the industry with a product people genuinely love — and we’re doing it while keeping fares affordable. That’s what high-value, low-cost means.”

Birthday Promotion

To celebrate five years in the skies, Breeze is offering 45% off the base fare on new round-trip flights booked from May 26 through May 29, 2026, using promo code BIRTHDAY, valid for travel between August 11, 2026, and January 30, 2027.

To learn more about Breeze or to book a flight, visit flybreeze.com or download the Breeze Airways app.

*45% base fare discount applies only to new reservations for roundtrip flights with promo code BIRTHDAY. Supply is limited, and no advance purchase requirement applies. Promotion must be purchased at FlyBreeze.com or on the Breeze app from May 26, 2026, through May 29, 2026 (11:59 pm PT), for travel from August 11, 2026, through January 30, 2027. Promotion excludes travel on September 7, 2026; from November 19, 2026, through November 30, 2026; and from December 17, 2026, through January 5, 2027. Travel must be flown on qualifying travel dates for the discount to be applied in full. The discount will apply only to flights on qualifying travel dates. All fare rules will apply. Certain flights and/or days of travel may be unavailable. Fare prices, fare classes, rules, routes, and schedules are subject to change or exemption without notice. Promotion cannot be combined with any other offer. Any changes or modifications to qualifying promotional reservations will be subject to fare repricing. A difference in airfare at the current fare price may apply. Offer not valid on group bookings. Other restrictions and blackout dates may apply.

About Breeze Airways

Breeze Airways operates more than 300 year-round and seasonal routes to 88 cities in the United States, Mexico, Central America and the Caribbean. Founded by aviation entrepreneur David Neeleman, Breeze took flight in May 2021 bringing high-value, low-cost nonstop air service to secondary markets on its flagship fleet of Airbus A220-300 aircraft. Breeze was named to the TIME100 Most Influential Companies list for 2026 and has been recognized as a top 4 “Best Domestic Airline” by Travel + Leisure for four consecutive years, the “Best Major Airline in North America” by the Airline Passenger Experience Association, and one of Fast Company’s “World’s Most Innovative Companies” for 2025. Breeze was the first U.S. domestic airline to be certified by Autism Double Checked and is the official airline of local Make-a-Wish chapters in Connecticut, South Carolina, and Utah. With seamless booking, friendly policies, and customized booking options, Breeze makes it easy to buy and Seriously Nice to fly.

Media Contact:

McKinnley Matson
corporatecommunications@flybreeze.com
(801) 436-3984
B-Roll | Newsroom 

The post Breeze Airways Celebrates Five Years of Making Air Travel Seriously Nice™ appeared first on Crypto Insider.

AUSTIN, Texas, May 27, 2026 (GLOBE NEWSWIRE) — Coder, the leader in self-hosted AI development infrastructure for the enterprise, today announced it has been named to Redpoint Ventures’ 2026 InfraRed 100, an annual list recognizing ascendant private companies that are building the foundational infrastructure powering the next wave of AI innovation.

As AI coding agents move into production, enterprises face a new infrastructure challenge in securely governing human and AI development workflows at scale. Coder solves this with self-hosted, agent-ready workspaces that give organizations consistent, isolated environments where developers and AI agents can securely access code, data, and compute under enterprise-controlled policies. This approach helps enterprises support AI-assisted and autonomous development while maintaining control over the environments where software is built.

“AI agents create a new set of requirements for the systems that run them,” said Rob Whiteley, CEO at Coder. “The need for secure sandboxes grows exponentially as agents like Claude Code and Codex are deployed to all knowledge workers. Coder’s inclusion in the InfraRed 100 highlights the need for infrastructure that supports this shift while meeting enterprise expectations for security and control.”

Redpoint is a venture capital firm that has invested at the leading edge of platform shifts for decades, backing generational companies like Snowflake, Twilio, Ramp, Stripe, HashiCorp, and Netflix. Redpoint launched the InfraRed 100 in 2023 to recognize emerging companies building the backbone of the AI era across developer tools, security, data, enterprise platforms, and beyond.

To learn more about Coder, visit the website.

About Coder
Coder is the leading platform for AI development Infrastructure, enabling enterprises to securely run human and AI-driven development workflows in consistent, governed environments. Coder provides self-hosted, agent-ready workspaces that unify developer productivity and platform governance. With Coder, enterprises can confidently evolve from human-only development to AI-assisted and autonomous workflows—without sacrificing security, compliance, or performance. Learn more at coder.com.

About Redpoint Ventures
Redpoint Ventures partners with founders redefining how people live and work through technology. Since 1999, Redpoint has invested across seed, early, and growth stages in companies including Snowflake, Stripe, Twilio, HashiCorp, Ramp, Netflix, Looker, and Nubank. The firm manages $7.0 billion across multiple funds. Learn more at redpoint.com.

Media Contact
Geena Pickering
Look Left Marketing
coder@lookleftmarketing.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c892c9e0-3370-4b5c-9b08-fdc509ae2190

The post Coder Named to Redpoint’s 2026 InfraRed 100 appeared first on Crypto Insider.

As stated in paragraph 6 in General Terms of Auction for Treasury bonds, the Government Debt Management offered the equivalent of 10% of the nominal value sold in the auction 22. May, at the price of accepted bids.

The post Results of additional issuance – RIKB 29 0416 – RIKS 37 0115 appeared first on Crypto Insider.

 Dubai, Kyiv and New York, May 26, 2026 – VEON Ltd. (Nasdaq: VEON), a global digital operator, today announced that Kyivstar Group Ltd. (Nasdaq: KYIV, KYIVW) (“Kyivstar”) has completed the acquisition of six solar power plants in the Lviv region of Ukraine, with a combined installed capacity of 105 megawatts (MW), for a total consideration of USD 80.8 million (UAH 3.6 billion). The solar assets being acquired generated approximately 113 GWh of electricity, while delivering approximately UAH 682 million of revenue and UAH 596 million of EBITDA in FY 2025, based on unaudited management accounts.

This acquisition expands Kyivstar’s renewable energy generation portfolio nearly ninefold and reflects VEON’s and Kyivstar’s continued investment in Ukraine’s infrastructure and energy sector. Following Kyivstar’s entry into renewable energy in December 2025 with the acquisition of the 13 MW Sunvin 11 solar power plant, Kyivstar’s total installed solar generation capacity now stands at 118 MW. The expected annual output from this combined portfolio is equivalent in volume to approximately 30% of Kyivstar’s current annual electricity consumption across its telecom operations.

Kyivstar will sell 100% of the electricity produced by the newly acquired solar power plants to Ukraine’s unified energy system in accordance with current market and regulatory rules. This enhances the company’s ability to hedge electricity costs by supplying energy from its solar power plants to the national grid at market prices with green energy tariffs, supporting operational efficiency as connectivity demand continues to expand across Ukraine.

“Kyivstar’s investment in renewable energy reflects VEON’s disciplined capital allocation in the markets we serve, deploying capital into infrastructure that generates revenue and provides a partial hedge against rising electricity costs,” said Kaan Terzioglu, Chief Executive Officer of VEON. “As Ukraine’s leading digital operator, Kyivstar plays a critical role in maintaining connectivity for millions of customers. This acquisition strengthens Kyivstar’s operational foundation while contributing to Ukraine’s energy sector development and advancing renewable energy generation.”

“Renewable energy is a key focus area of Kyivstar’s investment portfolio, and this acquisition opens further opportunities for the use of green electricity to meet the company’s energy needs,” said Oleksandr Komarov, President of Kyivstar. “The development of our own energy generation is an important component of our long-term vision aimed at building a safe, sustainable, and efficient infrastructure. Together with VEON, we continue to increase investments in the Ukrainian economy because we believe in Ukraine and its successful future.”

The acquisition of the new solar generation capacity was completed after signing of binding documentation earlier today with the seller, and regulatory approvals were received preceding the transaction.

A brief presentation with key information about this acquisition is available on the VEON website here.

About VEON
VEON is a digital operator that provides connectivity and digital services to over 150 million connectivity customers and more than 228 million digital users. Operating across five countries that are home to more than 6% of the world’s population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on NASDAQ. For more information, visit: https://www.veon.com. 

About Kyivstar Group Ltd.
Kyivstar Group Ltd. (“Kyivstar”) is a Nasdaq-listed holding company that operates JSC Kyivstar, Ukraine’s leading digital operator and the first Ukrainian company to list on a U.S. stock exchange. Kyivstar’s companies provide a broad range of connectivity and digital services, including mobile and fixed-line voice and data, ride-hailing, e-health, digital TV, and enterprise solutions such as Big Data, cloud, and cybersecurity. For more information, please visit https://investors.kyivstar.ua.

Forward-Looking Statements
This release contains “forward-looking statements”, within the meaning of the Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements relating to VEON’s strategy and investments in renewable energy, expected solar generation volumes, the anticipated economic effects of the transaction, and the partial hedging benefits described above. There are numerous risks, uncertainties that could cause actual results and performance to differ materially from those expressed by such statements, including risks relating to VEON’s and its subsidiaries’ strategic ambitions and their commercial partnerships, among others discussed in the section entitled “Risk Factors” in VEON’s 2025 Form 20-F filed with the SEC on March 16, 2026 and other public filings made by VEON with the SEC. The forward-looking statements contained herein speak only as of the date of this release and VEON disclaims any obligation to update them, except as required by law.

Additionally, this press release includes certain financial information and data of the acquired solar businesses derived from preliminary, unaudited management accounts as of the dates indicated and is subject to completion of customary financial closing, review, and audit procedures. This information is provided for informational purposes only and should not be regarded as a complete statement of financial results or relied upon as necessarily indicative of historical or future performance.

VEON press contact
pr@veon.com

The post VEON’s Kyivstar Expands Renewable Energy Portfolio with Acquisition of Six Solar Power Plants appeared first on Crypto Insider.